DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Zhu AX, Park JO, Ryoo BY et al.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol 2015;
16: 859-870
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.